News and Reports | February 9, 2026
Meanwhile, patient advocacy group Patients for Affordable Drugs Now (P4AD) had several misgivings about TrumpRx following the portal’s launch.
While the discounts on display will be especially useful for patients struggling to afford Novo and Eli Lilly’s GLP-1s, “these voluntary agreements lack clear enforcement mechanisms and still put the power to set and increase prices firmly in the hands of pharmaceutical corporations,” P4AD’s CEO Merith Basey said in a statement Thursday.
The nonprofit also pointed out that the pricing commitments companies have made are voluntary and not backed by statute, with no clear penalties if the drugmakers ultimately withdraw products or change their terms. TrumpRx also fails to address high wholesale acquisition costs, or list prices, which P4AD called the “underlying driver of high costs” for medicines in the U.S.